(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Annals of Hematology

• Publication date

  2018-12-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00277-018-3564-6PMID 30535802
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel agents for primary central nervous system lymphoma: evidence and perspectives.

  2018cited by this paper
• Two Cases of Pembrolizumab Therapy for CNS lymphoma (P6.136)

  2018cited by this paper
• Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

  2018cited by this paper
• Primary CNS Lymphoma.

  2017cited by this paper
• Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series

  2017cited by this paper
• Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

  2017cited by this paper
• PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.

  2017cited by this paper
• Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

  2016cited by this paper
• Primary CNS lymphoma

  2016cited by this paper
• Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network

  2016cited by this paper
• Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network

  2016cited by this paper
• Very High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory (R/R) Primary Central Nervous System (PCNSL) and Vitreo-Retinal (VRL) Non Hodgkin Lymphoma. a LOC Network Multicenter Retrospective Study on 58 Cases

  2015cited by this paper
• Safety and efficacy of primary central nervous system lymphoma treatment in elderly population

  2015cited by this paper
• [Therapeutic activity of gemcitabine in intracranial tumors].

  2015cited by this paper
• Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas

  2015cited by this paper
• Targetable genetic features of primary testicular and primary central nervous system lymphomas.

  2014cited by this paper
• Methotrexate re-challenge for recurrent primary central nervous system lymphoma

  2014cited by this paper
• Challenges in the treatment of elderly patients with primary central nervous system lymphoma.

  2014cited by this paper
• How I treat CNS lymphomas.

  2013cited by this paper
• Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

  2013cited by this paper
• Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial

  2012cited by this paper
• Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.

  2012cited by this paper
• Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma

  2011cited by this paper
• Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status

  2011cited by this paper
• Age, gender, and racial differences in incidence and survival in primary CNS lymphoma

  2011cited by this paper
• Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates

  2010cited by this paper
• High-dose methotrexate for elderly patients with primary CNS lymphoma.

  2009cited by this paper
• Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

  2009cited by this paper
• Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

  2009cited by this paper
• Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

  2008cited by this paper
• Temozolomide as salvage treatment in primary brain lymphomas

  2007cited by this paper
• GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II study

  2007cited by this paper
• Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma

  2007cited by this paper
• Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.

  2006cited by this paper
• Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors

  2006cited by this paper
• Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice

  2005cited by this paper
• Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

  2005cited by this paper
• Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas

  2004cited by this paper
• Treatment of Relapsed Central Nervous System Lymphoma with High-Dose Methotrexate

  2004cited by this paper
• Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide

  2004cited by this paper
• Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

  2003cited by this paper
• Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

  2003cited by this paper
• High-dose methotrexate for primary CNS lymphoma in the elderly.

  2000cited by this paper
• PCV salvage chemotherapy for recurrent primary CNS lymphoma

  2000cited by this paper
• Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.

  2000cited by this paper
• Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines

  1999cited by this paper

• Gemcitabine–oxaliplatin as a bridge therapy toward autologous hematopoietic stem cell transplantation in infant-type brain tumors

  2025cites this paper
• CAR T‐cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real‐life results of the LOC network

  2024cites this paper
• Novel Therapies for Primary Central Nervous System Lymphomas

  2024cites this paper
• Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma

  2023cites this paper
• Primary central nervous system lymphoma (PCNSL) in older patients.

  2023cites this paper
• HOW TO TREAT NEWLY-DIAGNOSED ELDERLY PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ? Induction therapy

  2023cites this paper
• European Association of Neuro-Oncology (EANO) Guidelines for Treatment of Primary Central Nervous System lymphoma (PCNSL).

  2022cites this paper
• Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review

  2021cites this paper
• Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies

  2020cites this paper
• Advances and challenges in the treatment of primary central nervous system lymphoma

  2020cites this paper
• OTT_A_192379 8323..8335

  2020cites this paper
• Multiple drugs

  2019cites this paper